A Regional Burden of Sequence-Level Variation in the 22q11.2 Region Influences Schizophrenia Risk and Educational Attainment

Elemi J. Breetvelt, Karel C. Smit, Jessica van Setten, Daniele Merico, Xiao Wang, Ilonca Vaartjes, Anne S. Bassett, Marco P.M. Boks, Peter Szatmari, Stephen W. Scherer, René S. Kahn, and Jacob A.S. Vorstman

ABSTRACT

BACKGROUND: Genomic loci where recurrent pathogenic copy number variants are associated with psychiatric phenotypes in the population may also be sensitive to the collective impact of multiple functional low-frequency single nucleotide variants (SNVs).

METHODS: We examined the cumulative impact of low-frequency, functional SNVs within the 22q11.2 region on schizophrenia risk in a discovery cohort and an independent replication cohort (N = 1933 and N = 11,128, respectively), as well as the impact on educational attainment (EA) in a third, independent, general population cohort (N = 2081). In the discovery and EA cohorts, SNVs were identified using genotyping arrays; in the replication cohort, whole-exome sequencing was available. For verification, we compared the regional SNV count for schizophrenia cases in the discovery cohort with a normative count distribution derived from a large population dataset (N = 26,500) using bootstrap procedures.

RESULTS: In both schizophrenia cohorts, an increased regional SNV burden (≥4 low-frequency SNVs) in the 22q11.2 region was associated with schizophrenia (discovery cohort: odds ratio = 7.48, p = .039; replication cohort: odds ratio = 1.92, p = .004). In the EA cohort, an increased regional SNV burden at 22q11.2 was associated with decreased EA (odds ratio = 4.65, p = .049). Comparing the SNV count for schizophrenia cases with a normative distribution confirmed the unique nature of the distribution for schizophrenia cases (p = .002).

CONCLUSIONS: In the general population, an increased burden of low-frequency, functional SNVs in the 22q11.2 region is associated with schizophrenia risk and a decrease in EA. These findings suggest that in addition to structural variation, a cumulative regional burden of low-frequency, functional SNVs in the 22q11.2 region can also have a relevant phenotypic impact.

https://doi.org/10.1016/j.biopsych.2021.11.019

The genetic architecture of schizophrenia is highly complex. Genetic variation contributing to its estimated heritability (64%–81%) (1–3) encompasses a spectrum of extremely rare to common variants with variable effect sizes (4,5). The cumulative effect of common and rare single nucleotide variants (SNVs) only explains a small fraction of the estimated heritability (6), suggesting a role for other types of genetic variations. Structural variation, including copy number variants (CNVs), represents one specific type of variation associated with the disease risk (7,8). A subset of recurrent CNVs shows a strong association with neurodevelopmental phenotypes, including schizophrenia (7,9–11), intellectual disability (ID), and autism spectrum disorder (12–14).

The observation that some CNVs are pathogenic while many others can occur with no apparent phenotypic consequences indicates that genomic regions differ with regard to the likelihood of phenotypic impact in the case of dosage change. At the same time, the neurodevelopmental phenotypes, e.g., schizophrenia or ID, associated with these large-effect structural variants are thought to be the result of the involvement of several genes affected by the CNV. Hence, a single deleterious single nucleotide variant (SNV) affecting only 1 gene at that locus typically does not have the same phenotypic consequences. Nevertheless, such genomic regions may be more liable than other regions to display phenotypic effects when affected by multiple SNVs (Figure 1). The question addressed by this study is whether a burden of SNVs in regions where pathogenic CNVs recurrently occur can, cumulatively, explain some of the genetic risk for neurodevelopmental outcomes.

We will examine this question with regard to the 22q11.2 region. CNVs recurrently occur in this region in the population, with the largest phenotypic impact exerted by the deletion associated with 22q11.2 deletion syndrome (22q11DS). With a prevalence estimated in the range of 1 in 3000 to 6000 live births (15), phenotypic manifestations of
22q11DS are highly variable and can affect multiple organ systems (16). Among others, the syndrome is strongly and consistently associated with an increased risk for both schizophrenia and other neurodevelopmental disorders, including ID (10,17).

Findings thus far suggest that a sequence-level disruption of a single gene within the 22q11.2 region is, in and of itself, not a strong risk factor for schizophrenia or ID. Accordingly, a recent study showed that the risk for schizophrenia in individuals with 22q11DS was not modified by SNVs in the remaining allele of the 22q11.2 region (18). Furthermore, genome-wide association study findings in the general population have not revealed any signal exerted by common risk variants in the 22q11.2 region (3). Taken together, these observations suggest that if deleterious SNVs in the 22q11.2 region contribute to the risk of schizophrenia or ID, then this would unlikely be the result of a single deleterious SNV. Therefore, we hypothesize that such effects may arise when several SNVs co-occur in this region, thereby mimicking the impact by a CNV in the same region. Hence, the cumulative burden of several SNVs in the 22q11.2 region may be of relevance.

Schizophrenia and ID, common neurodevelopmental phenotypes associated with the 22q11.2 deletion, do not occur entirely independently. Both low childhood cognitive level (19–22) and a decline thereof (22,23) are associated with the risk of developing schizophrenia in individuals with 22q11DS, echoing similar observations in the general population (24–26).

In addition, studies are starting to reveal substantial overlap between genetic variants associated with both phenotypes in the general population (27–29) and in 22q11DS (30). In the light of this growing body of evidence indicating a strong connection between academic/cognitive performance and schizophrenia (31), we examined both phenotypes in relation to the hypothesized phenotypic impact of a cumulative burden of putatively deleterious SNVs in the 22q11.2 region.

Figure 2 provides a schematic overview of this study. First, we examined the impact of the burden of SNVs in the 22q11.2 region on schizophrenia status in a schizophrenia case-control sample of 1933 individuals (discovery cohort). Second, we sought to replicate our findings in an independent schizophrenia case-control cohort (N = 11,128) while also extending the analysis from exome chip–based data to exome sequencing data (replication cohort). Third, in an independent population cohort (N = 2081), we examined whether the cumulative effect of multiple SNVs in the 22q11.2 region was also associated with decreased levels of educational attainment (EA) (validation cohort). Fourth, we conducted several post hoc analyses to further examine our observations.

METHODS AND MATERIALS

Study Populations

Discovery Cohort. The discovery cohort (N = 1933) consisted of 1002 patients with schizophrenia (cases) and 931 control subjects from the Netherlands (32). This cohort is relatively homogeneous because all participants were of Dutch
descent (defined as having at least 3 grandparents of Dutch ancestry). Cases were recruited from psychiatric institutions throughout the Netherlands, and diagnosis was based on a DSM-IV diagnosis of schizophrenia (33). Control subjects were volunteers who had no psychiatric history.

**Replication Cohort.** In the replication cohort (N = 11,128), we examined the association with schizophrenia in a second, independent cohort, details of which have been described previously (8,34). This cohort consisted of 4909 individuals with schizophrenia and 6219 control subjects from Sweden. Psychiatric cases with a diagnosis of schizophrenia were ascertained from the Swedish National Hospital Discharge Register as described in previous studies (5,35); this captures all inpatient hospitalizations. Control subjects were randomly selected from population registers.

**Validation Cohort.** For our study on the effect on EA, we used genotype and phenotype data available from 2081 participants of the Utrecht Health Project, an ongoing, population-based, longitudinal cohort study conducted in a newly developed residential area in the Netherlands (36). Data collected include demographics (sex, ethnicity, and age) and EA categorized into low (primary school), middle (high school), or high (college or university) EA. The number of participants in the minimal critical region group was relatively modest (19%); we therefore merged low and middle EA into one group (lower EA) in the initial analysis.

**Definition of 22q11.2 Region**

The 22q11.2 region is a structurally complex area of the genome that is characterized by multiple low-copy repeats (37–39). The two largest blocks, LCR22A and LCR22D, flank the most common ~3-Mb deletion in this region. The A-D deletion, a result of nonallelic homologous recombination between LCR22A and LCR22D, is present in approximately 85% of patients with 22q11DS (38,40). The ~1.5-Mb proximal deletion, flanked by LCR22A and LCR22B, is referred to as the minimal critical region because the approximately 5% to 10% of patients with 22q11DS with this smaller sized A-B deletion display the same (variable) phenotype, including cognitive and neurodevelopmental features, in particular schizophrenia. Consequently, we selected the minimal critical region, flanked by low-copy repeats A and B, for our analysis (10); this region contains approximately 30 protein-coding genes (16), (chromosome 22: 19.02 and chromosome 22: 20.26 Mb, respectively, GRCh37/hg19), henceforth referred to as the LCR22qA-B region.

**Genotyping**

DNA from participants in the discovery and validation cohorts were genotyped using the Illumina Infinium HumanExome BeadChip (version 1.1). This chip provides focused coverage for our analysis (10); this captures all inpatient hospitalizations. Control subjects were randomly selected from population registers.

**Analytic Methods**

In the discovery cohort, we determined the number of subjects per incrementally increasing count of SNVs (0, 1, 2, 3, and so on). For each SNV count, we calculated the ratio of individuals with schizophrenia to control subjects. Subsequently, we log-transformed the proportion of cases per SNV count, while grouping SNV counts above 5 into one bin (0, 1, 2, 3, 4, 5, or more). Based on this analysis, we established a threshold effect at a SNV burden of ≥4 SNVs at which the difference between cases and control subjects increases steeply. We used the two-sided Fisher’s exact test to test for significance.

In the replication cohort, we applied the same counting procedures as in the discovery sample. Subsequently, we used binary logistic regression with schizophrenia status as the outcome and an above-threshold SNV count as the predictor. The sample size of our replication cohort also allowed us to investigate the regional burden of SNVs without dichotomization around a threshold value (section 4 in Supplement 1). To this end, we repeated the analysis with the normalized SNV count as the predictor. In both analyses, we used sex and the first three components from the population stratification multidimensional scaling analysis (PLINK version 1.90b6), restricted to only the European samples, as covariates.

**Validation and Extending the Observations.** To further validate our findings, we extended our analysis, with EA as the phenotype of interest. We reiterated the procedure followed in the discovery cohort and compared the numbers of subjects
with lower EA versus high EA. We used the same cutoff for the SNV burden (≥4 SNVs) as in the discovery cohort. We also used this cutoff as predictor in a binary logistic regression model, with lower EA as outcome, and sex and age as covariates.

**Post Hoc Analyses**

We conducted the following post hoc analyses to examine the possible methodological or data-related factors that could influence our observations.

**Comparing the Observed to a Normative Count Distribution.** First, we examined the count distribution (i.e., number of subjects with 0, 1, 2, 3, and so on, SNVs) in each cohort to confirm their approximation of a Poisson distribution. We then used Database of Genotypes and Phenotypes (dbGaP) data to create an empirical normative distribution and compared this with the number of schizophrenia cases per SNV count in our discovery cohort. We used a dataset from dbGaP with more than 26,000 individuals from non-Hispanic European descent with exome data available. Importantly, these data were obtained with the same ExomeChip as the one used in the discovery cohort, allowing us to compare count distributions. We used a bootstrap procedure, taking 10,000 random samples from the dbGaP data, each time drawing the same number of subjects as the schizophrenia cases in the discovery cohort (N = 1002). Then, we determined the counts for each iteration and created empirical cutoffs of the mean and standard deviations for the expected number of subjects for each SNV count (0, 1, 2, 3, and so on).

**Potential Impact of EA Levels, SNV Types, Population Stratification, and Genome-wide SNV Rate.** To rule out any confounding due to our merging of educational levels, we repeated our analysis using the original three levels of EA as the outcome, ≥4 SNV burden as the predictor, and age and sex as covariates in an ordered logistic regression model.

The replication sample was sufficiently large to also reiterate the analysis for missense variants and for loss-of-function variants separately.

We considered the potential impact of population stratification in the three samples. In our discovery cohort, no significant influence of population stratification orcryptic relatedness had been shown by previous studies. In the replication cohort, we corrected for population stratification by using the first three components from the population stratification multidimensional scaling analysis. In the validation cohort, we examined possible confounding effects due to ethnicity by reanalyzing the data with the reported European origin as a covariate. In addition, to examine the possible effects of population stratification, we performed a principal component analysis and an analysis to detect relatedness in the validation cohort (section 8 in Supplement 1). We also examined whether the genome-wide SNV rate could account for the observed effect of the LCR22qA-B regional burden; no associations were observed between genome-wide and an increased regional burden in LCR22qA-B; in addition, no associations were observed between genome-wide SNV rates and phenotypic outcomes (section 9 in Supplement 1).

**Explore Impact of Increased Regional Burden of SNVs Across the Genome.** We examined the extent to which the observed phenotypic impact of an increased regional SNV burden is specific to the 22q11.2 LCR22A-B region. We reitered the exact same procedure to calculate the phenotypic effects of the above-threshold regional SNV burden for a set of randomly generated regions across the genome, each containing a similar number of consecutive SNV loci as observed in the 22q11.2 region. This permutation allowed us to place the impact of the SNV burden in 22q11.2 in the context of the distribution of SNV burden effects in similarly defined regions across the genome (section 5 in Supplement 1).

In addition, we explored the impact of the regional SNV burden in other genomic regions where recurrent CNVs are associated with schizophrenia (section 7 in Supplement 1).

**RESULTS**

**Primary Analysis**

Figure 3A, B shows the relationship between schizophrenia risk and the number of functional SNVs in the LCR22qA-B region. In our discovery cohort, a regional burden of four SNVs in the LCR22qA-B region marked a threshold beyond which a steep incline was observed for the proportion of schizophrenia cases, from 81.2% (4 SNVs) to 100% (≥5 SNVs). The incline in our independent replication cohort was more incremental but nevertheless indicative of a similar threshold. Based on the distribution of counts in the WES data, we identified a cutoff of 5 SNVs or more in our replication sample. Applying these cutoffs to the discovery and replication cohorts yielded comparable proportions of subjects with a similarly defined excess regional SNV burden (0.7% and 0.5%, respectively). The odds ratio (OR) of an above-threshold regional SNV burden in 22q11.2 on schizophrenia risk was 7.48 in the discovery cohort (95% CI = 1.00–31.98, p = .039) and 1.92 in the replication cohort (95% CI = 1.21–3.12, p = .004). The large sample size of the replication cohort also allowed us to examine the effect of a regional SNV burden in 22q11.2 without applying a threshold; beta was 0.052 (95% CI = 0.013–0.090, p = .008).

**Validation and Extension to EA**

The validation sample was derived from the general population (N = 2081), was 45% male, had a mean age of 39.3 (SD = 13.2) years, and was of 86% Dutch ethnicity. Regarding EA levels, 40.5% had attended college or university, and 59.5% had lower EA. Again, a regional burden of 4 SNVs in the LCR22qA-B region marked a threshold beyond which a steep incline was observed for the proportion of participants with a lower EA, from 59.5% lower EA in those with 0, 1, or 3 SNVs in 22q11.2 to 83.4% lower EA in those with 4 SNVs in this region.

Figure 4 shows the relationship between EA and SNV counts in the LCR22qA-B region. The effect size (OR) was 4.65 (95% CI = 1.00–21.56, p = .049).
Post Hoc Analyses

Compare to Normative Count Distribution. For all three cohorts, the counts followed a distribution approximating a Poisson distribution with a lambda of 0.46 for the discovery cohort, 0.93 for the replication cohort, and 0.46 for the validation cohort. The plot shows that until a SNV count of 3, cases and control subjects do not differentiate from each other. The number of control subjects with 4 SNVs decreases more rapidly compared with cases, and there are no control subjects with 5 or more SNVs. This is reflected in a steep incline in the proportion of cases at the threshold of 4 or more SNVs (from ~50% to ~86%). Note that the data do not indicate an incremental dosage effect. The results for the replication cohort, a schizophrenia case-control cohort using whole-exome sequencing data, show that until a SNV count of 4, cases and control subjects do not differentiate from each other. At 5 SNVs, the number of control subjects is for the first time smaller than that of cases, and the number of control subjects with 5 or more SNVs decreases more rapidly than the number of cases. This is reflected in an incline in the proportion of cases at the threshold of 5 or more SNVs (from ~43% to ~60%). In this case, the data indicate an incremental dosage effect but with an additional increase after the threshold. SNV, single nucleotide variant.

Potential Impact of EA Levels, SNV Types, and Population Stratification. The results from the ordered logistic regression confirmed the observed association between a regional burden of ≥4 SNVs at 22q11.2 (OR = 3.55, 95% CI = 1.34–9.74, p = .012) (section 2 in Supplement 1).

When restricting our analysis in the validation cohort to only missense variants, we observed a similar regional burden SNV
effect in the LCR22qA-B region on schizophrenia risk (OR = 1.94, \( p = .003 \)). Limiting the analysis to only loss-of-function variants yielded 387 subjects with one loss-of-function variant and only 2 subjects with two variants, precluding a regional burden analysis. The cases were not overrepresented in 387 subjects with one loss-of-function variant. The only subject with two loss-of-function variants in the LCR22qA-B region was a patient with schizophrenia.

The results of the principal component analysis confirmed the self-reported ethnicity status of the participants in the validation cohort and showed no indication for population stratification (section 7 in Supplement 1). There was also no indication of cryptic relatedness within the validation cohort.

Finally, we confirmed that our findings regarding the LCR22qA-B regional burden were not driven by increased genome-wide rates of SNVs (section 9 in Supplement 1).

**Explore the Impact of Potential Small Haploblocks.** Our exploratory analysis of the potential haploblocks contributing to the regional SNV burden in the LCR22qA-B region indicated that 7 of the 9 subjects in the discovery cohort and 10 of the 14 subjects in the validation cohort with the above-threshold regional SNV burden shared a haploblock consisting of 3 co-occurring SNVs, all located within the CLTCL1 gene. Note that the presence of this haploblock of 3 SNVs in CLTCL1 alone, i.e., without additional SNVs in the LCR22qA-B region, was not associated with schizophrenia (\( p = .66 \)) or with lower EA (\( p = 1.00 \)) (section 1 in Supplement 1). In the replication cohort, we observed the same CLTCL1 haploblock but also other correlated SNVs (combination of SNVs that co-occur in multiple subjects). The CLTCL1 haploblock was by itself again not associated with increased risk for schizophrenia (\( p = 1.00 \)). Correcting for the presence of the observed haploblocks did not alter the results for the replication sample, indicating that the CLTCL1 haploblock alone had no clinical impact; only in combination with additional SNVs did the association with the phenotype emerge.

**Explore Impact of Increased Regional Burden of SNVs Across the Genome.** In the distributions of effect sizes obtained in the replication and validation samples, the

![Figure 4](image.png)  
**Figure 4.** The effect of a SNV burden at the 22q11.2 A-B locus on the level of EA. The results are given for the validation cohort, a population-based cohort using the Human Exome BeadChip. The log-transformed number of subjects for each SNV count is given for subjects with a lower EA level compared with subjects with a high EA level. Furthermore, the proportion of subjects with a lower EA level is given for each SNV count. The plot shows that until a SNV count of 3, the two groups do not differentiate from each other. The number of subjects with a high EA level with 4 SNVs decreases more rapidly than for cases, and there are no subjects with a high EA level with 5 or more SNVs. This is reflected in a steep incline in the proportion of cases at the threshold of 4 or more SNVs (from ~60% to ~83.4%). Note that the data do not indicate an incremental dosage effect. EA, educational attainment; SNV, single nucleotide variant.
Phenotypic Impact of Regional SNV Burden at 22q11.2

We investigated the phenotypic impact of the cumulative burden of SNVs in regions with known recurrent pathogenic CNVs in three independent cohorts focusing on the 22q11.2 region, with schizophrenia and EA as the primary phenotypes of interest.

We showed that an elevated burden of low-frequency SNVs in the 22q11.2 region is associated with an increased risk of schizophrenia and a lower level of EA in the general population. These findings suggest that LCR22qA-B, a genomic region in which CNVs have a documented, strong phenotypic impact on schizophrenia risk and intelligence, is also vulnerable to the effect of a cumulative burden of low-frequency SNVs.

Our observation that an effect can be observed in the tail of the distribution of SNV counts (in just under 1%), suggests a threshold pattern, which is somewhat unexpected because studies examining the cumulative phenotypic impact of common variants generally indicate an additive-effect model (3,45–47). Possibly, the effect observed in this study is essentially different from genome-wide polygenic effects such as those implemented in polygenic risk scores. Instead, multiple hits in a vulnerable genomic region may be more similar to the phenotypic impact of a structural genetic variant in such regions. We suggest that this might also explain why classical genetic association studies have yet to identify causative SNVs in the 22q11.2 region, which seems at odds with the fact that this same region, when affected by a deletion, constitutes the single largest genetic risk factor of schizophrenia.

The convergence of phenotypic impact of SNV burden in the 22q11.2 region on both schizophrenia and EA is consistent with the hypothesized association between schizophrenia and cognitive ability (31). Recent evidence for shared, common genetic variants between schizophrenia and EA (27–29,48) is consistent with these results. For example, our results suggest a role of CLTCL1 in both schizophrenia risk and EA level. The potential relevance of CLTCL1 for brain development is suggested by the observation of a rare homozygous missense CLTCL1 mutation in a patient with severe ID (49) and a compound heterozygous mutation in a patient with infantile spasms (50). CLTCL1 is also one of the 709 genes associated with cognitive functions in a genome-wide association study in more than 300,000 individuals (27). Consistent with a burden effect, we found that carriers of a CLTCL1 haploblock were at increased risk of lower EA or schizophrenia only if the same haploblock concurred with at least 1 additional SNV in the LCR22qA-B region.

The limitations of our study include the relatively small sample size of the discovery cohort, resulting in large CIs. In addition, the predetermined, and somewhat restricted, number of SNVs on the exome chip may be considered as a limitation to the generalizability of our finding in the discovery cohort. However, we have addressed both limitations by seeking replication of our discovery findings in a large replication cohort with WES data. In this sample, we observed essentially the same effect, albeit with a higher SNV count threshold, which is not unexpected given the several-fold higher number of SNV calls in the WES data compared with the exome chip data. We surmise that extending the observed impact of a regional SNV burden in the 22q11.2 region across two phenotypes further strengthens our findings.

Winners’ curse probably plays a role in the observed, smaller effect size in the replication cohort; another possible explanation is that the control group in the latter included subjects with other psychiatric diagnoses as well as individuals with lower EA. Finally, similar to most large-scale genetic studies, our study population consisted mainly of participants of European descent. It is unclear whether the relationship between increased regional burden and risk of schizophrenia differs across populations, but it needs to be explored in future studies (51).
Results from our permutation analysis indicate that the phenotypic impact of a regional SNV burden in the 22q11.2 region is higher than in most other regions across the genome with a similar number of consecutive SNVs. While the focus of this study is on the 22q11.2 region, the existence of other genomic regions with similar susceptibility for the cumulative effect of multiple regional SNVs is highly probable. Our future studies will expand on the principle presented here, among others, by examining the phenotypic impact of a regional SNV burden in other genomic regions recurrently affected by pathogenic CNVs. Indeed, the 22q11.2 region is only one of multiple hot spot regions in the human genome where segmental duplications increase the probability of recurrent pathogenic CNVs (52). As a result, CNVs can recur at these loci in the population, despite their negative impact on neurocognitive function and reproductive fitness in affected individuals. Many genes in these regions with human-specific segmental duplications are associated with brain development, function, and disease (53,54).

The regional burden approach could potentially contribute to explaining a part of the missing heritability, possibly with observed effect sizes between the strong phenotypic impacts for some of the rare variants (6) and the small effect sizes observed in common variants.

In summary, we report that an increased regional burden of protein-altering SNVs in the LCR22qA-B region confers a risk of schizophrenia as well as a negative impact on EA in the general population. Our results suggest that it may be worthwhile to study the regional burden of low-frequency SNVs in other genomic regions, in particular those known to be vulnerable to recurrent pathogenic CNVs with neurodevelopmental impact.

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the Mr. Rajeel Mulkerjee B.Sc. (Hons.) (London School of Economics) Fellowship in Schizophrenia (to EJB), an academic scholarship award from the Department of Psychiatry at the University of Toronto (to EJB), the O’Brien Scholarship (to EJB), and the National Institutes of Mental Health (Grant No. U01MH110722-02 [to JASV]).

DM is a full-time employee of Deep Genomics Inc. and is entitled to a stock option. JASV serves as a consultant for NoBias Therapeutics Inc. SWS is on the Scientific Advisory Committees of Deep Genomics and Population Bio and is a highly cited Academic Consultant for the King Abdul Aziz University. All other authors report no biomedical financial interests or potential conflicts of interests.

ARTICLE INFORMATION

From the Department of Psychiatry (EJB, PS, JASV), The Hospital for Sick Children; Department of Psychiatry (EJB, ASB, PS, JASV), University of Toronto; Center for Applied Genomics, Genomics and Genome Biology (DM, XW, SWS), The Hospital for Sick Children; Deep Genomics Inc. (DM); Dalhousie Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome (ASB); Toronto General Hospital, University Health Network; Clinical Genetics Research Program (ASB), Centre for Addiction and Mental Health; Division of Clinical and Metabolic Genetics (ASB), The Hospital for Sick Children; Medical Genetics and Genomics Residency Training Program (ASB), University of Toronto; Toronto General Research Institute (ASB); Campbell Family Mental Health Research Institute (ASB); McLaughlin Centre and Department of Molecular Genetics (SWS), University of Toronto; the Program in Genetics and Genome Biology (JASV), Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Psychiatry (KCS, MPMB, RSK, JASV), University Medical Center Utrecht Brain Center; Department of Cardiology (JvS), and Department of Medical Oncology (KCS), University Medical Center Utrecht, University of Utrecht; Department of Epidemiology (KCS, IV), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands; and Department of Psychiatry (RSK), Icahn School of Medicine at Mount Sinai, NewYork, New York.

Address correspondence to Elemi J. Breetvelt, M.D., Ph.D., at Elemi.Breetvelt@sickkids.ca.

Received Apr 17, 2021; revised Oct 25, 2021; accepted Nov 12, 2021. 
Supplementary material cited in this article is available online at https://doi.org/10.1016/j.biopsych.2021.11.019.

REFERENCES


